Kymera Therapeutics to Report Third Quarter 2026 Financial Results
Kymera Therapeutics, Inc. announced it will report its third quarter 2026 financial results on October 29, 2026.
Stocks · News reference
Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results
Kymera Therapeutics, Inc. announced it will report Phase 1 clinical trial results for its oral IRF5 degrader, KT-579, on October 29, 2026, in conjunction with its third-quarter 2026 financial results.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This American Express Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiate coverage: Outperform on American Express and Kymera, Overweight on Kratos, Hold on IBM and Neutral on Duos.
Raymond James Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $140